4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Lexeo Therapeutics, Inc. (LXEO) operates in the Biotechnology industry and is headquartered in New York, United States with about 59 employees. Its market capitalization is roughly $368 million. In the fiscal year ended 2025-12-31, LXEO reported $0M in revenue and ($100M) in net income.
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $1M | — |
| Operating Income (EBIT) | ($109M) | ($106M) | ($68M) | ($60M) | — |
| Net Income | ($100M) | ($98M) | ($66M) | ($59M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($22M) | ($23M) | ($22M) | ($31M) | ($34M) |
| Net Income | ($20M) | ($21M) | ($20M) | ($26M) | ($33M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $269M | $147M | $140M | $97M | — |
| Total Liabilities | $22M | $30M | $26M | $210M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive LXEO viewer.
About TickerBase · Data methodology & sources